Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Bioshares Biotech Summit 2026
29 slides from Amplia Therapeutics's conference presentation, Aug 6, 2026
Slide 1: Bioshares Biotech Summit Presentation – Targeting Pancreatic Cancer and Beyond
06 AUGUST 2026 ASX RELEASE BIOSHARES BIOTECH SUMMIT PRESENTATION – TARGETING PANCREATIC CANCER AND BEYOND Amplia Therapeutics Limited (“ATX” or “the Company”) releases its Bioshares Biotech Summit Presentation which Managing Director Dr Chris Burns will present at the Bioshares Biotech For personal
Slide 2: About Narmafotinib and trials
first-line patients. The trial has achieved its desired outcome in achieving a response rate of 36%, superior to chemotherapy alone as reported for the benchmark MPACT study. A median Overall Survival (mOS) of 11.1 months has been reported along with an unprecedented complete response rate of 7.8%.
Slide 3: Targeting pancreatic cancer and beyond
Targeting For personal use only pancreatic cancer and beyond BIOSHARES 2026 ampliatx.com | @ampliatx ASX: ATX | OTCQB: INNMF 1
Slide 4: Disclaimer
2 Disclaimer This presentation (Presentation) contains summary information about Amplia Therapeutics Limited ACN Forward-looking statements are based on the Company’s good faith assumptions as to the financial 165 160 841 and its subsidiaries (the Company or Amplia) which is current as at 30 Jun 202
Slide 5: The FAK Opportunity
3 The FAK Opportunity A large and unmet clinical need exists in cancers where FAK is overexpressed Lead program Pancreatic Cancer Ovarian Cancer kRAS Combinations For personal use only US$3.2b market1 US$5.8b market2 US$7.8b market (by 2035)3 Exciting data from ACCENT Trial PRROSE Trial Emerging opp
Slide 6: Targeting fibrosis and resistance
4 Targeting fibrosis and resistance Narmafotinib breaks down fibrosis surrounding the tumour, and blocks survival and resistance pathways in cancer cells Chemotherapy For personal use only NARMAFOTINIB FAK drives a dense fibrous Narmafotinib acts to reduce Chemotherapy can now matrix that surrounds
Slide 7: ACCENT Trial in pancreatic cancer
For personal use only ACCENT Trial in pancreatic cancer Excellent tolerability and responses observed 5
Slide 8: ACCENT Pancreatic Cancer Trial
6 ACCENT Pancreatic Cancer Trial Phase 1b/2a clinical trial in Australia and South Korea For personal use only Narmafotinib plus standard-of-care Narmafotinib Chemotherapy chemotherapy Newly diagnosed patients Metastatic disease Taken orally in 64 patients at top dose narmafotinib days preceding Thr
Slide 9: ACCENT Pancreatic Cancer Trial
7 ACCENT Pancreatic Cancer Trial Narmafotinib + gemcitabine / abraxane in first-line advanced pancreatic cancer For personal use only 7.8% 70% 11.1months months No Extra Burden Complete Disease Median Safety & response rate control rate overall survival tolerability Superior to chemo alone Chemo alo
Slide 10: ACCENT Pancreatic Cancer Trial
8 ACCENT Pancreatic Cancer Trial Narmafotinib + gemcitabine / abraxane in first-line advanced pancreatic cancer For personal use only Deep and sustained tumour shrinkage OS related to Response White circles indicate patients alive at March review
Slide 11: ACCENT registration pathway
9 ACCENT registration pathway A three-part registration pathway designed around FDA feedback Underway Details to be confimed Details to be confimed ACCENT Mini ACCENT Reg - P2b ACCENT Reg - P3 For personal use only Daily dosing at two dose levels Builds on ACCENT Mini data to Pivotal registrational
Slide 12: kRAS Inhibitors
For personal use only kRAS Inhibitors An exciting new class of anti-cancer therapies - ideally suited for FAK inhibitor combination 10
Slide 13: kRAS mutations prevalent in cancer
11 kRAS mutations prevalent in cancer Significant cancer driver in multiple indications 100 Clinical studies demonstrating For personal use only 80 good activity but resistance and % kRAS Prevalence tolerability a significant issue 60 A market growing at 35% per year 40 From $526M today to a project
Slide 14: Significant competition in development
12 Significant competition in development Combinations critical to development strategy Chugai Kestrel G12C G12D Lilly Roche pan For personal use only Amgen Erasca Pfizer BridgeBio Genhouse Alterome Qilu Frontier Astellas Verastem RevMed RevMed Astellas AZ RevMed HuyaBio SJ Pharma Hansoh Bayer Innov
Slide 15: The Opportunity Ahead
13 The Opportunity Ahead Combinations critical to development strategy For personal use only
Slide 16: Narmafotinib and kRAS inhibition
14 Narmafotinib and kRAS inhibition Overcoming acquired resistance to kRAS inhibitors FAK signaling is an escape mechanism to For personal use only blockade of RAS pathway Growing evidence for clinical benefit of FAK + kRAS inhibition Approval of defactinib + avutometinib (Co-Pack) in kRAS mutant LG
Slide 17: Narmafotinib and kRAS inhibition
15 Narmafotinib and kRAS inhibition Overcoming acquired resistance to kRAS inhibitors FAK signaling is an escape mechanism to For personal use only blockade of RAS pathway Growing evidence for clinical benefit of FAK + kRAS inhibition Approval of defactinib + avutometinib (Co-Pack) in kRAS mutant LG
Slide 18: Lilly Collaboration - Background
16 Lilly Collaboration - Background Enhancing efficacy for next-generation kRAS G12C inhibitor FDA-approved G12C targeted drugs - first Drug Trial Setting mPFS mOS ORR For personal use only generation Adagrasib (BMS); Sotorasib (Amgen) Adagrasib KRYSTAL-12 Phase 3 5.5 mos Immature 31.9% 2L+ NSCLC Cl
Slide 19: Lilly Collaboration - Detail
17 Lilly Collaboration - Detail Enhancing efficacy for next-generation kRAS G12C inhibitor Previously treated KRAS G12C-mutant advanced or Phase 1b metastatic NSCLC For personal use only Olomorasib (100 mg, BID) Phase 1b/2b study Narmafotinib Narmafotinib Narmafotinib (200 mg, QD) (400 mg, QD) (600
Slide 20: Lilly Collaboration
18 Lilly Collaboration Important validation of the potential of our science Eli Lilly and Co. Lilly Oncology Pipeline Market Cap US$1.1 T For personal use only Marketed oncology drugs Verzenio (abemaciclib) Jaypirca (pirtobrutinib) Retevmo (selpercatinib) A deep pipeline of small molecules drugs, ra
Slide 21: PRROSE Trial in ovarian cancer
For personal use only PRROSE Trial in ovarian cancer Building on promising preclinical and literature data 19
Slide 22: Ovarian Cancer
20 Ovarian Cancer 70% of patients are diagnosed at advanced stage where 5-year survival is 20% For personal use only 20% of patients will be resistant or develop resistance during initial treatment 50% of an ovarian tumour is fibrotic - a key driver of drug resistance
Slide 23: PRROSE Trial
21 PRROSE Trial The study is an investigator-initiated clinical trial led by Dr Gwo Yaw Ho of Monash Health and Monash University, and sponsored and coordinated through ANZGOG For personal use only ~20 Patients Treatment Surgery Endpoints HGSOC Narmafotinib + interval debulking Safety, surgical elig
Slide 24: Development Timeline
22 Development Timeline 2026 2027 2028 2029 ACCENT For personal use only ACCENT-mini safety data ACCENT-reg FDA Meeting FDA Meeting PRROSE
Slide 25: Development Timeline
23 Development Timeline 2026 2027 2028 2029 ACCENT For personal use only ACCENT-mini safety data ACCENT-reg FDA Meeting FDA Meeting Olomorasib combination KRASi combination 2 PRROSE
Slide 26: Development Timeline
24 Development Timeline 2026 2027 2028 2029 ACCENT For personal use only ACCENT-mini safety data ACCENT-reg FDA Meeting FDA Meeting KRASi arm Olomorasib combination KRASi combination 2 PRROSE
Slide 27: Corporate Summary
25 Corporate Summary ASX:ATX | OTCQB:INNMF 12 month share price chart Share price A$0.155 (04-Aug-2026) For personal use only Shares on 513.3M issue Market cap A$79.56M (04-Aug-2026) Cash at hand A$24.0M (30-Jun-2026) Platinum Investment Management Ltd Substantial Acorn Capital Ltd Shareholders Blue
Slide 28: Board and Management
26 Board and Management World-class expertise SENIOR MANAGEMENT BOARD Rhiannon Jones PhD GAICD For personal use only COO Jason Lickliter MBBS FRACP CMO Jane Bell AM Warwick Tong Robert Peach Brett Carter Chris Burns LLB LLM (Lond) FAICD MB ChB MPP GAICD PhD BSc MBA GAICD PhD GAICD FAHMS Chair Direct
Slide 29: Thank You
Thank You For personal use only Chris Burns PhD GAICD FAHMS Rhiannon Jones PhD GAICD CEO and MD COO chris@ampliatx.com rhiannon@ampliatx.com Amplia Therapeutics Limited ASX: ATX | OTCQB: INNMF info@ampliatx.com ampliatx.com